Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mitochondrial ATP synthase alpha-subunit, encoded by the ATP5F1A gene, is a core component of the F1 catalytic domain of the ATP synthase complex (Complex V) located in the inner mitochondrial membrane (UniProt: P25705). It plays a fundamental role in energy metabolism by facilitating the synthesis of ATP from ADP and inorganic phosphate, driven by the proton gradient across the membrane (PubMed: 29166580). Beyond its canonical role in the mitochondria, the alpha-subunit is known to be ectopically expressed on the surface of various cells, including tumor and endothelial cells, where it acts as a receptor for ligands like angiostatin, influencing angiogenesis and tumor growth (PubMed: 10591212). Mutations in this subunit are linked to severe mitochondrial disorders, such as neonatal-onset encephalopathy and hypertrophic cardiomyopathy, due to impaired oxidative phosphorylation (NCBI Gene: 498). In therapeutic contexts, it is explored as a target for anti-cancer agents and in the study of autoimmune conditions like systemic lupus erythematosus, where surface expression triggers immune responses (PubMed: 24554717). However, the essential nature of ATP synthase in nearly all eukaryotic cells presents significant challenges for drug safety, as non-specific inhibition can lead to profound systemic toxicity and metabolic failure.
Inhibition of the F1 catalytic subunit to prevent ATP synthesis or hydrolysis; modulation of the mitochondrial permeability transition pore (mPTP) opening; and serving as a cell-surface receptor for anti-angiogenic factors when ectopically expressed (PubMed: 10591212, 16407415).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATP synthase subunit alpha, mitochondrial (ATP5F1A) (ATP5F1A).